Bone Metastases Are Measurable: The Role of Whole-Body MRI and Positron Emission Tomography

Metastatic tumor deposits in bone marrow elicit differential bone responses that vary with the type of malignancy. This results in either sclerotic, lytic, or mixed bone lesions, which can change in morphology due to treatment effects and/or secondary bone remodeling. Hence, morphological imaging is...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Daniela E. Oprea-Lager, Matthijs C.F. Cysouw, Ronald Boellaard, Christophe M. Deroose, Lioe-Fee de Geus-Oei, Egesta Lopci, Luc Bidaut, Ken Herrmann, Laure S. Fournier, Tobias Bäuerle, Nandita M. deSouza, Frederic E. Lecouvet
Formato: article
Lenguaje:EN
Publicado: Frontiers Media S.A. 2021
Materias:
MRI
PET
Acceso en línea:https://doaj.org/article/db6da3777d2d4d689a6875c00aa6665e
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:db6da3777d2d4d689a6875c00aa6665e
record_format dspace
spelling oai:doaj.org-article:db6da3777d2d4d689a6875c00aa6665e2021-11-19T06:22:40ZBone Metastases Are Measurable: The Role of Whole-Body MRI and Positron Emission Tomography2234-943X10.3389/fonc.2021.772530https://doaj.org/article/db6da3777d2d4d689a6875c00aa6665e2021-11-01T00:00:00Zhttps://www.frontiersin.org/articles/10.3389/fonc.2021.772530/fullhttps://doaj.org/toc/2234-943XMetastatic tumor deposits in bone marrow elicit differential bone responses that vary with the type of malignancy. This results in either sclerotic, lytic, or mixed bone lesions, which can change in morphology due to treatment effects and/or secondary bone remodeling. Hence, morphological imaging is regarded unsuitable for response assessment of bone metastases and in the current Response Evaluation Criteria In Solid Tumors 1.1 (RECIST1.1) guideline bone metastases are deemed unmeasurable. Nevertheless, the advent of functional and molecular imaging modalities such as whole-body magnetic resonance imaging (WB-MRI) and positron emission tomography (PET) has improved the ability for follow-up of bone metastases, regardless of their morphology. Both these modalities not only have improved sensitivity for visual detection of bone lesions, but also allow for objective measurements of bone lesion characteristics. WB-MRI provides a global assessment of skeletal metastases and for a one-step “all-organ” approach of metastatic disease. Novel MRI techniques include diffusion-weighted imaging (DWI) targeting highly cellular lesions, dynamic contrast-enhanced MRI (DCE-MRI) for quantitative assessment of bone lesion vascularization, and multiparametric MRI (mpMRI) combining anatomical and functional sequences. Recommendations for a homogenization of MRI image acquisitions and generalizable response criteria have been developed. For PET, many metabolic and molecular radiotracers are available, some targeting tumor characteristics not confined to cancer type (e.g. 18F-FDG) while other targeted radiotracers target specific molecular characteristics, such as prostate specific membrane antigen (PSMA) ligands for prostate cancer. Supporting data on quantitative PET analysis regarding repeatability, reproducibility, and harmonization of PET/CT system performance is available. Bone metastases detected on PET and MRI can be quantitatively assessed using validated methodologies, both on a whole-body and individual lesion basis. Both have the advantage of covering not only bone lesions but visceral and nodal lesions as well. Hybrid imaging, combining PET with MRI, may provide complementary parameters on the morphologic, functional, metabolic and molecular level of bone metastases in one examination. For clinical implementation of measuring bone metastases in response assessment using WB-MRI and PET, current RECIST1.1 guidelines need to be adapted. This review summarizes available data and insights into imaging of bone metastases using MRI and PET.Daniela E. Oprea-LagerDaniela E. Oprea-LagerMatthijs C.F. CysouwRonald BoellaardChristophe M. DerooseChristophe M. DerooseChristophe M. DerooseLioe-Fee de Geus-OeiLioe-Fee de Geus-OeiEgesta LopciLuc BidautLuc BidautKen HerrmannLaure S. FournierLaure S. FournierLaure S. FournierTobias BäuerleNandita M. deSouzaNandita M. deSouzaNandita M. deSouzaFrederic E. LecouvetFrederic E. LecouvetFrontiers Media S.A.articlebone metastasesMRIPETmeasurableresponseNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENFrontiers in Oncology, Vol 11 (2021)
institution DOAJ
collection DOAJ
language EN
topic bone metastases
MRI
PET
measurable
response
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
spellingShingle bone metastases
MRI
PET
measurable
response
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
Daniela E. Oprea-Lager
Daniela E. Oprea-Lager
Matthijs C.F. Cysouw
Ronald Boellaard
Christophe M. Deroose
Christophe M. Deroose
Christophe M. Deroose
Lioe-Fee de Geus-Oei
Lioe-Fee de Geus-Oei
Egesta Lopci
Luc Bidaut
Luc Bidaut
Ken Herrmann
Laure S. Fournier
Laure S. Fournier
Laure S. Fournier
Tobias Bäuerle
Nandita M. deSouza
Nandita M. deSouza
Nandita M. deSouza
Frederic E. Lecouvet
Frederic E. Lecouvet
Bone Metastases Are Measurable: The Role of Whole-Body MRI and Positron Emission Tomography
description Metastatic tumor deposits in bone marrow elicit differential bone responses that vary with the type of malignancy. This results in either sclerotic, lytic, or mixed bone lesions, which can change in morphology due to treatment effects and/or secondary bone remodeling. Hence, morphological imaging is regarded unsuitable for response assessment of bone metastases and in the current Response Evaluation Criteria In Solid Tumors 1.1 (RECIST1.1) guideline bone metastases are deemed unmeasurable. Nevertheless, the advent of functional and molecular imaging modalities such as whole-body magnetic resonance imaging (WB-MRI) and positron emission tomography (PET) has improved the ability for follow-up of bone metastases, regardless of their morphology. Both these modalities not only have improved sensitivity for visual detection of bone lesions, but also allow for objective measurements of bone lesion characteristics. WB-MRI provides a global assessment of skeletal metastases and for a one-step “all-organ” approach of metastatic disease. Novel MRI techniques include diffusion-weighted imaging (DWI) targeting highly cellular lesions, dynamic contrast-enhanced MRI (DCE-MRI) for quantitative assessment of bone lesion vascularization, and multiparametric MRI (mpMRI) combining anatomical and functional sequences. Recommendations for a homogenization of MRI image acquisitions and generalizable response criteria have been developed. For PET, many metabolic and molecular radiotracers are available, some targeting tumor characteristics not confined to cancer type (e.g. 18F-FDG) while other targeted radiotracers target specific molecular characteristics, such as prostate specific membrane antigen (PSMA) ligands for prostate cancer. Supporting data on quantitative PET analysis regarding repeatability, reproducibility, and harmonization of PET/CT system performance is available. Bone metastases detected on PET and MRI can be quantitatively assessed using validated methodologies, both on a whole-body and individual lesion basis. Both have the advantage of covering not only bone lesions but visceral and nodal lesions as well. Hybrid imaging, combining PET with MRI, may provide complementary parameters on the morphologic, functional, metabolic and molecular level of bone metastases in one examination. For clinical implementation of measuring bone metastases in response assessment using WB-MRI and PET, current RECIST1.1 guidelines need to be adapted. This review summarizes available data and insights into imaging of bone metastases using MRI and PET.
format article
author Daniela E. Oprea-Lager
Daniela E. Oprea-Lager
Matthijs C.F. Cysouw
Ronald Boellaard
Christophe M. Deroose
Christophe M. Deroose
Christophe M. Deroose
Lioe-Fee de Geus-Oei
Lioe-Fee de Geus-Oei
Egesta Lopci
Luc Bidaut
Luc Bidaut
Ken Herrmann
Laure S. Fournier
Laure S. Fournier
Laure S. Fournier
Tobias Bäuerle
Nandita M. deSouza
Nandita M. deSouza
Nandita M. deSouza
Frederic E. Lecouvet
Frederic E. Lecouvet
author_facet Daniela E. Oprea-Lager
Daniela E. Oprea-Lager
Matthijs C.F. Cysouw
Ronald Boellaard
Christophe M. Deroose
Christophe M. Deroose
Christophe M. Deroose
Lioe-Fee de Geus-Oei
Lioe-Fee de Geus-Oei
Egesta Lopci
Luc Bidaut
Luc Bidaut
Ken Herrmann
Laure S. Fournier
Laure S. Fournier
Laure S. Fournier
Tobias Bäuerle
Nandita M. deSouza
Nandita M. deSouza
Nandita M. deSouza
Frederic E. Lecouvet
Frederic E. Lecouvet
author_sort Daniela E. Oprea-Lager
title Bone Metastases Are Measurable: The Role of Whole-Body MRI and Positron Emission Tomography
title_short Bone Metastases Are Measurable: The Role of Whole-Body MRI and Positron Emission Tomography
title_full Bone Metastases Are Measurable: The Role of Whole-Body MRI and Positron Emission Tomography
title_fullStr Bone Metastases Are Measurable: The Role of Whole-Body MRI and Positron Emission Tomography
title_full_unstemmed Bone Metastases Are Measurable: The Role of Whole-Body MRI and Positron Emission Tomography
title_sort bone metastases are measurable: the role of whole-body mri and positron emission tomography
publisher Frontiers Media S.A.
publishDate 2021
url https://doaj.org/article/db6da3777d2d4d689a6875c00aa6665e
work_keys_str_mv AT danielaeoprealager bonemetastasesaremeasurabletheroleofwholebodymriandpositronemissiontomography
AT danielaeoprealager bonemetastasesaremeasurabletheroleofwholebodymriandpositronemissiontomography
AT matthijscfcysouw bonemetastasesaremeasurabletheroleofwholebodymriandpositronemissiontomography
AT ronaldboellaard bonemetastasesaremeasurabletheroleofwholebodymriandpositronemissiontomography
AT christophemderoose bonemetastasesaremeasurabletheroleofwholebodymriandpositronemissiontomography
AT christophemderoose bonemetastasesaremeasurabletheroleofwholebodymriandpositronemissiontomography
AT christophemderoose bonemetastasesaremeasurabletheroleofwholebodymriandpositronemissiontomography
AT lioefeedegeusoei bonemetastasesaremeasurabletheroleofwholebodymriandpositronemissiontomography
AT lioefeedegeusoei bonemetastasesaremeasurabletheroleofwholebodymriandpositronemissiontomography
AT egestalopci bonemetastasesaremeasurabletheroleofwholebodymriandpositronemissiontomography
AT lucbidaut bonemetastasesaremeasurabletheroleofwholebodymriandpositronemissiontomography
AT lucbidaut bonemetastasesaremeasurabletheroleofwholebodymriandpositronemissiontomography
AT kenherrmann bonemetastasesaremeasurabletheroleofwholebodymriandpositronemissiontomography
AT lauresfournier bonemetastasesaremeasurabletheroleofwholebodymriandpositronemissiontomography
AT lauresfournier bonemetastasesaremeasurabletheroleofwholebodymriandpositronemissiontomography
AT lauresfournier bonemetastasesaremeasurabletheroleofwholebodymriandpositronemissiontomography
AT tobiasbauerle bonemetastasesaremeasurabletheroleofwholebodymriandpositronemissiontomography
AT nanditamdesouza bonemetastasesaremeasurabletheroleofwholebodymriandpositronemissiontomography
AT nanditamdesouza bonemetastasesaremeasurabletheroleofwholebodymriandpositronemissiontomography
AT nanditamdesouza bonemetastasesaremeasurabletheroleofwholebodymriandpositronemissiontomography
AT fredericelecouvet bonemetastasesaremeasurabletheroleofwholebodymriandpositronemissiontomography
AT fredericelecouvet bonemetastasesaremeasurabletheroleofwholebodymriandpositronemissiontomography
_version_ 1718420345640189952